Denecimig clinical trials
Also written Mim8.
How each study uses denecimig is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the denecimig studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses denecimig is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia ARecruitingPhase 3Novo Nordisk A/SNCT07830732Written as Denecimig
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia AActive, not recruitingPhase 3Novo Nordisk A/SNCT05685238Written as Mim8
- A Research Study Investigating Mim8 in People With Haemophilia ACompletedPhase 2Novo Nordisk A/SNCT04204408Written as NNC0365-3769 (Mim8)
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedPhase 3Novo Nordisk A/SNCT05053139Written as NNC0365-3769 (Mim8)
- A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)CompletedPhase 3Novo Nordisk A/SNCT05878938Written as NNC0365-3769 (Mim8) PPX
- A Research Study Looking at Mim8 in Children With Haemophilia A With or Without InhibitorsCompletedPhase 3Novo Nordisk A/SNCT05306418Written as Mim8
- A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and CartridgeCompletedPhase 1Novo Nordisk A/SNCT05681845Written as NNC0365-3769 (Mim8)
Codes
What other systems call denecimig · ClinicalTrials.gg INT016484
- UNII (FDA) EUV85RR8DJDENECIMIGOne source FDA
- NCI Thesaurus C190437DenecimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | EUV85RR8DJ | DENECIMIG | One source FDA |
| NCI Thesaurus | C190437 | Denecimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.